Coronavirus Disease 2019 (COVID-19) Analyst Consensus Sales Analysis and Forecast, H2 2022

Coronavirus Disease 2019 (COVID-19) Analyst Consensus Sales Analysis and Forecast, H2 2022

Summary

This report contains a summary of the analyst consensus forecasts available in the GlobalData Pharma Intelligence Center Drug Sales and Analyst Consensus Database for the Indication COVID-19. Currently there are 52 drugs indicated for COVID-19 which have analyst consensus forecasts available.

Scope

This report gives important, expert insight you won’t find in any other source. 16 figures throughout the report illustrate major points and trends in COVID sales forecasts and company pipelines. This report is required reading for -

• Investors that want to understand how COVID-19 has impacted Drug Revenues in the biopharmaceutical industry as well as identifying companies to invest in
• Companies that are interested in entering the COVID-19 disease space
• Large pharma companies with investment groups or BD teams looking for partnership opportunities in the COVID-19 disease space

• Analysis of COVID-19 analyst consensus sales forecasts
• Detailed Analysis of how COVID-19 have affected analyst consensus sales forecasts for previously forecasted Drugs Detailed Analysis of how COVID-19 forecasts changed from 2020 to 2022 and what drove these changes